← Back to Search

Implant

NT-501 for Macular Telangiectasia

Phase 3
Waitlist Available
Led By Emily Chew, MD
Research Sponsored by Neurotech Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through 24 months.
Awards & highlights

Study Summary

This trial is testing a new treatment for macular telangiectasia type 2, a condition that causes vision loss. The treatment, NT-501 implants, is being compared to the current standard of care. The study will measure how well the treatment works and how safe it is.

Eligible Conditions
  • Macular Telangiectasia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through 24 months.
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through 24 months. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Rate of Change in Ellipsoid Zone (EZ) Area Loss
Secondary outcome measures
Mean Change in Aggregate Sensitivity of Microperimetry
Mean Change in Reading Speed
National Eye Institute-Visual Function Questionnaire (NEI-VFQ)

Side effects data

From 2019 Phase 2 trial • 22 Patients • NCT01530659
5%
Reversible Cardiac Vasospasm
5%
Secondary Surgical Intervention (excluding Posterior Capsulotomy)
5%
Pelvic fracture
5%
Pregnancy
5%
Total Eye Disorders
100%
80%
60%
40%
20%
0%
Study treatment Arm
Sham Surgery
Prior to Randomization
NT-501 Implant

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: NT-501Experimental Treatment1 Intervention
Group II: ShamPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
NT-501
2017
Completed Phase 3
~390

Find a Location

Who is running the clinical trial?

Neurotech PharmaceuticalsLead Sponsor
10 Previous Clinical Trials
533 Total Patients Enrolled
1 Trials studying Macular Telangiectasia
64 Patients Enrolled for Macular Telangiectasia
Emily Chew, MDPrincipal InvestigatorNational Eye Institute (NEI)
3 Previous Clinical Trials
1,653 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2
2018. "A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03319849.
~16 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top